FASN and metabolic dysfunction-associated steatotic liver disease: Our findings thus indicate that the therapeutic efficacy of hepatic FASN inhibition for NAFLD and T2D might be determined by the etiology of obesity, which should be taken into account in follow-up investigations in humans.